Meeting
2011 ASCO Annual Meeting
MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules.
Authors
J. S. Kauh
Winship Cancer Institute of Emory University, Atlanta, GA
J. S. Kauh , G. Shapiro , R. B. Cohen , J. W. Clark , R. D. Harvey , J. M. Cleary , D. Mahalingam , S. Kuan , A. McDonald , A. Berger , B. Dezube , J. Sarantopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
New Targets, New Technologies
Clinical Trial Registration Number
NCT00677170
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3013)
Abstract #
3013
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.
First Author: Jian-Ming Xu
Poster
2013 ASCO Annual Meeting
Phase I study of c-Met inhibitor ARQ197 in combination with FOLFOX for the treatment of patients with advanced solid tumors.
First Author: Suzanne Fields Jones
Poster
2011 ASCO Annual Meeting
Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs).
First Author: M. Kittaneh
Poster
2024 ASCO Annual Meeting
A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.
First Author: Toshihiko Doi